Validation of the Performance of the French Version of the Cerebellar Cognitive-Affective Syndrome Scale (CCASS) as a Screening Test for Cerebellar Cognitive-affective Syndrome: a National Multicenter Study
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
217 participants
Nov 9, 2023
INTERVENTIONAL
Conditions
Summary
The primary objective of the study is to assess the performance of the French version of the Cerebellar Cognitive-Affective Syndrome Scale (CCASS) as a screening test for cerebellar cognitive-affective syndrome. The primary endpoint will be the sensitivity of version 1A of the French scale. The result will be considered positive if the patient fails at least one of the scale's subtests. The diagnosis of a cerebellar cognitive-affective syndrome will be made on the basis of a pathological score in the executive, language, visuospatial or psychoaffective domains of the neuropsychological evaluation (gold standard).
Eligibility
Inclusion Criteria11
- French speaking
- Acquired lesion or predominantly degenerative cerebellar pathology of any etiology
- Affiliated or beneficiary of a social security scheme
- Written informed consent
- History or progressive pathology of the central nervous system other than cerebellar disease
- Chronic ethylic patient with active consumption, or alcohol withdrawal of less than three months
- Use of other toxic substances
- Blind or severely visually impaired patient
- Deaf or severely hearing-impaired patient unable to understand instructions
- Mute patient
- Patient deprived of liberty or under legal protection
Exclusion Criteria1
- \- Patients with incomplete French scale and/or neuropsychological assessment will be replaced.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The CCASS will be administered by a neuropsychologist starting with version 1A. An alternative version (1B, 1C or 1D) will also be administered. An interval of approximately 30 minutes should be observed between the two administrations. In order to assess the inter-rater reliability of the scale, a second neuropsychologist will be present in the room and will independently evaluate (i.e., blind to his/her colleague's rating) patient's responses. The choice of alternative version (i.e., 1B, 1C, or 1D) will be randomized.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06005844